Abstract:2
AbstractObjective: To evaluate the effect size of type 2 diabetes mellitus (T2DM) on tuberculosis (TB) treatment outcomes and multi drug resistance (MDR).
Methods:A cohort with 507 individuals with diagnosed TB included 183 with coexistence of T2DM and TB (TB-T2DM). Participants were identified at the time of TB diagnosis and followed during the course of TB treatment. Then we computed relative risks and adjustments by Cox proportional hazards for outcome variables (drug resistance, death, relapse, treatment… Show more
“…Patients with diabetes–TB co‐infection are more likely to remain positive after initial antitubercular treatment, and to exhibit higher resistance to frontline drugs. Moreover, these people are more likely to have multidrug‐resistant TB, treatment failure, and relapse, as reported in another study from Mexico …”
“…Patients with diabetes–TB co‐infection are more likely to remain positive after initial antitubercular treatment, and to exhibit higher resistance to frontline drugs. Moreover, these people are more likely to have multidrug‐resistant TB, treatment failure, and relapse, as reported in another study from Mexico …”
“…Since 2010, several large cohort studies reported unfavourable effects of DM on TB outcomes. DM was associated with more severe clinical manifestations of TB such as higher frequency of cavities on chest X‐ray and higher hospitalization rates . Patients with DM were more likely to have up to 2 times higher TB reactivation, recurrence, and relapse .…”
Section: Introductionmentioning
confidence: 95%
“…DM was associated with more severe clinical manifestations of TB such as higher frequency of cavities on chest X‐ray and higher hospitalization rates . Patients with DM were more likely to have up to 2 times higher TB reactivation, recurrence, and relapse . TB‐DM patients were more likely to have delayed sputum conversion and higher probability of treatment failure .…”
Section: Introductionmentioning
confidence: 98%
“…Patients with DM were more likely to have up to 2 times higher TB reactivation, recurrence, and relapse . TB‐DM patients were more likely to have delayed sputum conversion and higher probability of treatment failure . A recent systematic review showed that glycaemic control has a favourable effect on TB treatment outcomes and, conversely, uncontrolled DM or poor glycaemic control (i.e.…”
Aims
With a prevalence of 16%, diabetes mellitus (DM) is one of the most frequent non‐communicable comorbidities of tuberculosis (TB). DM is a major risk factor for adverse TB outcomes and may require personalized TB drug dosing regimens. However, information on the inclusion of DM in TB drug trials is lacking. We aimed to assess the percentage of recent TB drug efficacy trials that included DM patients.
Methods
A systematic review was performed and reported according to PRISMA guidelines. PubMed, Science Direct, and http://ClinicalTrials.gov databases were systematically searched for TB drug trials published between 1 January 2012 and 12 September 2017. Primary outcome was the percentage of TB drug trials performed around the world that included DM patients.
Results
Out of the included 41 TB drug trials, 12 (29.3%) reported DM comorbidity among the study participants. Nine trials (21.9%) excluded all patients with DM comorbidity, ten (24.4%) excluded only insulin‐dependent or uncontrolled DM, and 10 (24.4%) did not mention whether DM was included or excluded. Of the 12 trials that included DM comorbidity, the majority did not report the diagnostic criteria for DM and none reported outcomes in the DM subpopulation. Inclusion of DM was higher in drug‐resistant‐TB trials (67%, P = .003, vs drug‐susceptible) and trials performed in Asia (60%, P = .006, vs Africa).
Conclusions
Fewer than 1/3 recent TB drug trials reported the inclusion of DM. To better reflect real‐world DM prevalence and differential TB drug effectiveness, inclusion of DM patients requires increased attention for future TB drug trials.
“…Diabetes predisposes to tuberculosis due to the profound effects of hyperglycemia on body defense mechanisms including suppression of cell-mediated immune mechanisms [10]. It is also well known that presence of diabetes mellitus also alters the way pulmonary tuberculosis manifests and adversely affects clinical and treatment outcomes [11]. It also results in slow conversion to a sputum-negative state [12].…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.